MedPath

MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial

Not Applicable
Completed
Conditions
Borderline Personality Disorder
Registration Number
NCT02068326
Lead Sponsor
Psychiatric Research Unit, Region Zealand, Denmark
Brief Summary

Background: Although it is now possible to diagnose Borderline Personality Disorder (BPD) in adolescents younger than 18 years according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), and studies indicates that BPD can be reliably diagnosed in adolescence, only a few evidence based treatment programmes for adolescent BPD exists. Mentalization-based treatment (MBT), including group psychotherapy, has repeatedly shown to be effective in treating adult BPD, but in the case of adolescents, only individual MBT have been tested and found to be effective.

Aims/hypotheses: We will test whether group based MBT (MBT-G), including an introductory programme for patients (MBT-I) and their parents (MBT-P) is more effective than Treatment As Usual (TAU) in treating adolescents with BPD or subthreshold BPD.

Methods/Design: 112 patients referred to child and adolescent psychiatric clinics in Region Zealand will be randomized to either MBT or TAU. Inclusion criteria: Meeting DSM-V BPD-criteria at the threshold (five criteria) or sub threshold level (4 criteria). Follow-up will be at three and 12 months.

Discussion: Early intervention is especially important in relation to personality psychopathology and has long-term benefits for patients, their families and society. In addition to being cost effective, using the group modality in the treatment of BPD may have several advantages. This is the first Randomized Controlled Trial (RCT) to test the effectiveness of MBT in groups for adolescents.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
112
Inclusion Criteria
  • Meet a minimum of 4 DSM-5 BPD criteria
  • Have parent's or parent substitute's commitment and ability to participate in the MBT-Parents program.
  • Score 67< BPFS-C
Exclusion Criteria
  • Comorbid diagnosis of pervasive developmental disorder, learning disability (75 < IQ), anorexia, current psychosis, diagnosis of schizophrenia or schizotypal personality disorder, antisocial personality disorder as well as any other axis-I or axis-II psychopathology considered to be the primary diagnosis.
  • Current psychiatric inpatient treatment
  • Current (past two months) substance dependence (but not substance misuse)
  • Participation in concurrent psychotherapeutic treatment outside the MBT program
  • Not able to speak Danish
  • Lack of informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The Borderline Personality Feature Scale for Children (BPFS-C)Change from baseline at 30 weeks
Secondary Outcome Measures
NameTimeMethod
The childhood behaviour checklist (CBCL, Parental outcome measure)Change from baseline at 30 weeks
The borderline personality feature scale for Children - parental version (BPFS-P)Change from baseline at 30 weeks
Number of patients' hospital admissions and visits to the emergency roomChange from baseline at 40 weeks
The Youth Self-Report (YSR)Change from baseline at 40 weeks
Becks Depression Inventory for YouthChange from Baseline in at 40 weeks
ZAN-BPD Zanarini Rating Scale for Borderline Personality DisorderChange from baseline at 40 weeks
The Health of the Nation Outcome Scale for Children and Adolescent (HoNOSCA)Change from baseline at 40 weeks
The Childrens' Global Assessment Scale (CGAS)Change from baseline at 40 weeks
The Risk-Taking and Self-Harm Inventory for adolescents (RTSHIA)Chage from baseline at 30 weeks

Trial Locations

Locations (1)

Child and Adolescent Psychiatric Department, Region Zealand

🇩🇰

Roskilde, Region Zealand, Denmark

Child and Adolescent Psychiatric Department, Region Zealand
🇩🇰Roskilde, Region Zealand, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.